1. Home
  2. TXMD vs NSRX Comparison

TXMD vs NSRX Comparison

Compare TXMD & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

HOLD

Current Price

$1.98

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.14

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXMD
NSRX
Founded
2008
2019
Country
United States
Israel
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
25.8M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
TXMD
NSRX
Price
$1.98
$3.14
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
22.6K
130.0K
Earning Date
05-12-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
73.68
N/A
EPS
N/A
N/A
Revenue
$1,761,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
35.25
N/A
52 Week Low
$0.98
$1.98
52 Week High
$2.95
$9.99

Technical Indicators

Market Signals
Indicator
TXMD
NSRX
Relative Strength Index (RSI) 39.25 51.17
Support Level $1.94 $2.16
Resistance Level $2.05 $4.49
Average True Range (ATR) 0.12 0.45
MACD -0.01 0.06
Stochastic Oscillator 12.50 30.77

Price Performance

Historical Comparison
TXMD
NSRX

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: